JP2021504370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504370A5 JP2021504370A5 JP2020528867A JP2020528867A JP2021504370A5 JP 2021504370 A5 JP2021504370 A5 JP 2021504370A5 JP 2020528867 A JP2020528867 A JP 2020528867A JP 2020528867 A JP2020528867 A JP 2020528867A JP 2021504370 A5 JP2021504370 A5 JP 2021504370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- unit dosage
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 12
- 230000007882 cirrhosis Effects 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- 208000019423 liver disease Diseases 0.000 claims description 9
- 201000001883 cholelithiasis Diseases 0.000 claims description 8
- 102100038495 Bile acid receptor Human genes 0.000 claims description 4
- 206010056375 Bile duct obstruction Diseases 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 208000001130 gallstones Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593084P | 2017-11-30 | 2017-11-30 | |
| US62/593,084 | 2017-11-30 | ||
| PCT/IB2018/059383 WO2019106550A1 (en) | 2017-11-30 | 2018-11-28 | Fxr agonists for the treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504370A JP2021504370A (ja) | 2021-02-15 |
| JP2021504370A5 true JP2021504370A5 (https=) | 2022-01-06 |
Family
ID=64959384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528867A Pending JP2021504370A (ja) | 2017-11-30 | 2018-11-28 | 肝疾患を治療するためのｆｘｒ作動薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210361638A1 (https=) |
| EP (1) | EP3716977A1 (https=) |
| JP (1) | JP2021504370A (https=) |
| KR (1) | KR20200094175A (https=) |
| CN (1) | CN111356458A (https=) |
| AU (1) | AU2018376904B2 (https=) |
| CA (1) | CA3081656A1 (https=) |
| IL (1) | IL274747A (https=) |
| MX (1) | MX2020005557A (https=) |
| RU (1) | RU2020121222A (https=) |
| TW (1) | TW201936189A (https=) |
| WO (1) | WO2019106550A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021014349A1 (en) * | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| WO2021064575A1 (en) * | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1734970T3 (pl) * | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| ES2902404T3 (es) * | 2016-02-22 | 2022-03-28 | Novartis Ag | Métodos para utilizar agonistas de fxr. |
| ES2862194T3 (es) * | 2016-02-22 | 2021-10-07 | Novartis Ag | Métodos para usar agonistas del FXR |
| MX384205B (es) * | 2016-02-22 | 2025-03-14 | Novartis Ag | Metodos para usar agonistas de fxr. |
| AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
-
2018
- 2018-11-28 EP EP18830302.8A patent/EP3716977A1/en not_active Withdrawn
- 2018-11-28 US US16/767,078 patent/US20210361638A1/en not_active Abandoned
- 2018-11-28 KR KR1020207017973A patent/KR20200094175A/ko not_active Ceased
- 2018-11-28 RU RU2020121222A patent/RU2020121222A/ru unknown
- 2018-11-28 WO PCT/IB2018/059383 patent/WO2019106550A1/en not_active Ceased
- 2018-11-28 US US16/202,637 patent/US20190161483A1/en not_active Abandoned
- 2018-11-28 MX MX2020005557A patent/MX2020005557A/es unknown
- 2018-11-28 AU AU2018376904A patent/AU2018376904B2/en not_active Ceased
- 2018-11-28 TW TW107142391A patent/TW201936189A/zh unknown
- 2018-11-28 CN CN201880074342.4A patent/CN111356458A/zh active Pending
- 2018-11-28 CA CA3081656A patent/CA3081656A1/en active Pending
- 2018-11-28 JP JP2020528867A patent/JP2021504370A/ja active Pending
-
2020
- 2020-05-18 IL IL274747A patent/IL274747A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2018507914A5 (https=) | ||
| JP6762931B2 (ja) | 経鼻組成物と該経鼻組成物の使用方法の改善 | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| JP2018514534A5 (https=) | ||
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| ES2701094T3 (es) | Tratamiento de enfermedades colestáticas intrahepáticas | |
| JP2020503269A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| JP2011528355A5 (https=) | ||
| JP2016530279A5 (https=) | ||
| CN102655859A (zh) | 病毒感染的组合疗法治疗 | |
| JP2020500864A5 (https=) | ||
| JP2014521641A5 (https=) | ||
| HUE025567T2 (en) | Agents containing vasoconstrictors for combination therapy | |
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| JP2021504370A5 (https=) | ||
| CA3163375A1 (en) | Treatment of primary biliary cholangitis with elafibranor | |
| JP2016505050A5 (https=) | ||
| RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
| JP2019507786A5 (https=) | ||
| JP2020519576A5 (https=) | ||
| CN101654393A (zh) | 作为肝脏保护剂的化合物和组合物 | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use |